Skip to main content

Table 1

From: A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures

  Surface molecules (MFI)
  CD80 CD86 CD40
Unactivated DC    
Media Control 571.7 (± 23) 1194 (± 125) 29.5 (± 1.5)
Lipiodol Control 567.3 (± 21) 1251 (± 173) 28.6 (± 1.3)
Mixed siRNA 572.5 (± 10) 1365 (± 157) 29.7 (± 1.3)
siRNA alone 559.6 (± 33) 1201 (± 193) 30.1 (± 0.9)
siRNA + Lipiodol 577.3 (± 15) 1195 (± 103) 30.4 (± 1.3)
Post-MLR    
Lipiodol Control 1962.9 (± 136) 2707.1 (± 576) 140.5 (± 35.4)
Mixed siRNA 1933.2 (± 324) 3031.6 (± 489) 170.3 (± 26.9)
siRNA alone 1905.7 (± 351) 2759.9 (± 392) 167.2 (± 46.9)
siRNA + Lipiodol 2050.8 (± 119) 3051.1 (± 335) 153.3 (± 36.7)
Post-MLR + Anti-IL10    
Lipiodol Control 3529 (± 302) 4862 (± 583) 236.0 (± 47.3)
Mixed siRNA 3442 (± 247) 4777 (± 773) 242.8 (± 58.9)
siRNA alone 3723 (± 453) 4863 (± 669) 237.4 (± 43.5)
siRNA + Lipiodol 3985 (± 339) 4957 (± 501) 254.3 (± 49.3)
  1. Surface staining for FACS analysis was performed using anti-CD11c Ab (gated DC) and anti-CD80, CD86 or CD40 Abs (MFI values). Samples stained with the appropriate isotype-matched control Abs were analyzed in parallel to establish the gating criterion. Results are representative of at least three independent experiments for each culture condition.